CBD SEO — Rank a Hemp-Derived CBD Brand Without Paid Ads

Pure traffic isn't the ceiling. Most CBD brands plateau at the same trickle of "best CBD oil" searches because everyone fights the same head terms. We work three layers at once.

Layer 1 — head terms ("cbd oil for sleep", "broad-spectrum CBD") — slow, brutal, but non-negotiable for trust signals. Layer 2 — long-tail intent ("is CBD safe with melatonin?", "does CBD show up on a drug test?") — where AEO citations land first because the answers are factual and AI loves factual. Layer 3 — entity authority — the brand's named expert, peer-reviewed studies cited, FDA warning-letter awareness, all of which compound over 12+ months and become why ChatGPT picks your brand to quote when asked "what's a reputable CBD brand."

We also track AI-Overview placement weekly across ChatGPT, Perplexity, Gemini, Claude and Google AI Overviews. First placements typically land 30–90 days in.

As of 2026, Google Ads does not allow CBD products in the US, except for a narrow allowlist of certified topicals through select advertisers. Meta technically allows CBD topicals but flags most accounts within days. Pinterest restricts. TikTok bans. The free-acquisition stack is search and content.

What this means in practice: every dollar you would have spent on Google Ads gets reallocated to organic. That changes which channels matter most. Paid-search shops that pivoted to CBD typically discover their playbook is 50% useless — the keyword research and conversion-rate work transfer, but the bidding, attribution and creative-velocity muscle becomes irrelevant. SEO and content take over, plus link velocity through HARO, podcasts and trade press.

Side effect: when paid is off, organic competition concentrates. The brands that win the SEO marathon get an outsized share of the pipeline.

A regular DTC site can get away with thin product copy and a star-rating widget. A CBD site cannot. Google ranks CBD inside YMYL (Your Money or Your Life) territory because ingestible products affect health. That triggers the strictest E-E-A-T evaluation: named author, named medical reviewer, peer-reviewed citations, FDA-disclaimer placement, contraindications, and dosage discussions that don't make medical claims.

We deploy: a named expert byline (typically the founder or a medical advisor), `Person` schema with credentials, FDA disclaimer in every product page, structured Quick-Facts panel with COA (Certificate of Analysis) link, ingredient transparency, and Review/AggregateRating wired to a real review platform — not Yotpo-only star widgets that AI models can't extract.

We also deploy a `MedicalCondition`-adjacent set of FAQ pages structured for AEO extraction: every condition-related question gets a ≤30-word direct answer followed by a longer evidence-backed body, because that's the format ChatGPT and Google AI Overviews lift verbatim.

Month 1: technical baseline ships — schema, llms.txt, robots.txt for AI crawlers, FDA disclaimer, age-gate (where required), Core Web Vitals. Homepage and 4 priority pages restructure under the AEO playbook (X-is-Y intro, Quick Facts, H2-as-question, FAQ direct-answer ≤30 words). 4 blog posts publish.

Month 3: schema is live, the priority pages are crawled, the first long-tail FAQ pages start ranking. AI citations begin appearing for branded queries and long-tail factual queries first — head terms take longer. We've shipped ~12 new posts and 1–2 location pages by now.

Month 6: rankings movement is visible on 5–15 priority queries. AI citations are weekly across 2–3 platforms. The named-expert byline starts getting press mentions through HARO and outreach. From here it compounds. Brands that stay 12+ months typically see 3–5× organic traffic and become the brand AI engines cite first when asked about their category.